Evidence map›Paper›PMID 40067824›Full record

ArticleSTAR protocols2025

Protocol for the simultaneous activation and lentiviral transduction of primary human T cells with artificial T cell receptors.

Jordan Yong Ming Tan, Jia Chi Tan, Chuqi Wang, Ling Wu, Nicholas R J Gascoigne, Shruti Bhatt

Abstract read
In one paragraph

Article in STAR protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Pandora's Box of AML: HowBiomedicines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jordan Yong Ming TanDepartment of Pharmacy & Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 18 Science Drive 2, Singapore 117543, Singapore. Electronic address: jordantanym@u.nus.edu.
Jia Chi TanDepartment of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Cancer Translational Research Programme, Yong Loo Lin School School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.
Chuqi WangDepartment of Pharmacy & Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 18 Science Drive 2, Singapore 117543, Singapore.
Ling WuDepartment of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Cancer Translational Research Programme, Yong Loo Lin School School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.
Nicholas R J GascoigneDepartment of Microbiology & Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; Cancer Translational Research Programme, Yong Loo Lin School School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore.
Shruti BhattDepartment of Pharmacy & Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 18 Science Drive 2, Singapore 117543, Singapore. Electronic address: shruti_bhatt@nus.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell-based therapies hold immense promise, but their production remains time-consuming and technically complex. Here, we present a protocol that streamlines the activation and lentiviral transduction of primary human T cells with artificial receptors. We describe steps for T cell isolation, lentivirus production, and the simultaneous activation/transduction of T cells. By eliminating magnetic T cell activation beads, sequential steps, and lengthy spinoculation, this protocol significantly enhances efficiency, scalability, and accessibility for research and therapeutic applications.

Indexed as

LentivirusReceptors, Antigen, T-CellReceptors, ArtificialT-LymphocytesTransduction, GeneticGenetic VectorsHEK293 CellsHumansLymphocyte ActivationReceptors, Antigen, T-CellReceptors, ArtificialCancerCell cultureGene expressionImmunologyMolecular biology

Identifiers

PMID40067824
PMCPMC11950759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.